Previous 10 | Next 10 |
– Preclinical data supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission in 2H 2023 – – Additional data presented on SENTI-301A and crIL-15 support Senti’s development of gene circuit enhanced CA...
SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the foll...
2023-03-22 17:24:28 ET Senti Biosciences press release ( NASDAQ: SNTI ): Q4 GAAP EPS of -$0.42. As of December 31, 2022, Senti Bio held cash, cash equivalents and short-term investments of $98.6 million, For further details see: Senti Biosciences GAAP EPS of -$0.42
- SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS - - Preclinical data from multiple Gene Circuit enhanced CAR NK programs to be presented at Ameri...
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that Tim Lu, MD, Ph...
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors – – SENTI-202 on track for IND filing in 2H...
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that Tim Lu, MD, PhD, ...
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is advancing toward clinical development for hematologic malignancies – ȁ...
– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML – – Live and webcast event on Sunday, December 11, 11:30 am - 12:30 pm CST ...
Senti Biosciences press release ( NASDAQ: SNTI ): Q3 GAAP EPS of -$0.38 beats by $0.12 . Revenue of $1.77M (+60.9% Y/Y) beats by $0.84M . As of September 30, 2022, Senti Bio held cash and cash equivalents of $114.9 million, which the Company believes is suffici...
News, Short Squeeze, Breakout and More Instantly...
Senti Biosciences Inc. Company Name:
SNTI Stock Symbol:
NASDAQ Market:
Senti Biosciences Inc. Website:
2024-07-18 09:02:04 ET SNTI (SNTI) announced stock split at a ratio of 1-for-10 on 2024-07-18 ... Full story available on KlickAnalytics.com
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that its Board of Directors h...
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...